Lepitrim
This article was originally published in The Tan Sheet
Executive Summary
Dietary supplements containing the patented compound Lepitrim are expected to reach the market through direct sellers by the end of the first quarter of 2006, Imagenetix announces. Expansion to mass market distribution is expected in the second quarter. The San Diego, Calif.-based firm signed a licensing agreement with the University of Minnesota and will market the ingredient as a raw material, according to a Nov. 16 announcement. Lepitrim lowers levels of leptin, a hormone that causes fat storage. When leptin levels are low, fat is released to be burned as energy by the body, Imagenetix says. A one-month supply is expected to cost $55 - $65. The firm is submitting structure/function claims that include "Assists in lowering body fat" and "Promotes the reduction of stored fat by increasing fatty acid utilization in the fat cell"...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.